Pharma Journalist -

Synplogen Co., a synthetic biology startup spun out of Kobe University's Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy…
Read More...

Ipsen and GENFIT announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily dual…
Read More...

Solid Biosciences Inc., a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that it has received Fast Track Designation from…
Read More...

AbelZeta Pharma Inc. (the Company, or AbelZeta), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer,…
Read More...

Arvinas, Inc. and Pfizer Inc. announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination…
Read More...

With the recent FDA-approvals of Bayer’s Eylea HD 8mg as a durable long-term treatment for Wet AMD and Genentech’s Vabysmo for Retinal Vein Occlusion (RVO), now is the time to unite…
Read More...

AbbVie Inc. and BigHat Biosciences announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with…
Read More...

Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma …
Read More...

With Novartis joining the suprachoroidal race with their novel injector and Genentech's re-designed sustained release formulations showing promise for wet AMD, there has never been a…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination…
Read More...